Sana Biotech­nol­o­gy snags Os­cine, adding cell ther­a­py leader Steve Gold­man to its star-stud­ded staff

Sana Biotech­nol­o­gy CEO Steve Harr be­gan kick­ing around the idea of ac­quir­ing Os­cine ear­ly on in the com­pa­nies’ part­ner­ship. About a year ago, over din­ner with the Uni­ver­si­ty of Rochester Med­ical Cen­ter spin­out’s CEO and sci­en­tif­ic founder, he pulled the trig­ger.

The part­ners re­al­ized it was “the right thing to do. (And) then it usu­al­ly takes a lot longer than you hope… to get things done,” Harr said. On Fri­day, the com­pa­nies an­nounced they got it done.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER